IPOpulse
Back to Ticker

JB Chemicals & Pharmaceuticals Limited

NSE: JBCHEPHARM
Healthcare Healthcare
₹2,408.9
-3.87%EOD · 16 Jul

JB Chemicals & Pharmaceuticals Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹38,793 Cr
52W Range
₹2526 / ₹1675
Volume
4779K
66.8% delivery
1Y Return
—
P/E Ratio
54.2
P/B Ratio
9.3
ROE
18.7%
Debt / Equity
0.09

Peers in Healthcare

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
JB Chemicals & Pharmaceuticals Limited(this stock)₹2,408.9₹38,793 Cr54.29.318.7%0.77%
Divi's Laboratories LimitedDIVISLAB₹9,087₹2.41 L Cr83.014.516.2%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM₹4,558.7₹1.73 L Cr72.818.417.0%0.83%
Laurus Labs LimitedLAURUSLABS₹2,069₹1.12 L Cr101.821.017.7%0.12%
Zydus Lifesciences LimitedZYDUSLIFE₹1,113.9₹1.11 L Cr25.04.218.3%0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP₹7,700₹1.11 L Cr54.312.021.5%0.25%
Aurobindo Pharma LimitedAUROPHARMA₹1,621.4₹93,292 Cr26.12.69.9%0.00%
Mankind Pharma LimitedMANKIND₹2,253.2₹93,067 Cr46.05.812.4%0.00%
Max Healthcare Institute LimitedMAXHEALTH₹830₹80,785 Cr56.77.714.3%0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice
B
56/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityStrong · 83
ValuationPoor · 20
MomentumGood · 55
Low debt (D/E ≤ 0.3)

Technical Indicators

205d data — partial · objective math, not advice
Returns
1D
-3.9%
1W
-1.5%
1M
+9.9%
3M
+21.6%
6M
+26.1%
1Y
—
RSI (14)
71 Overbought
RS vs Nifty (3M)
+27.3pp
Moving Averages (price vs MA)
20-DMA
₹2344
above
50-DMA
₹2241
above
150-DMA
₹2046
above
200-DMA
₹1966
above
From 52W High
-4.6%
From 52W Low
+47.0%
Support (20D)
₹2163
Resistance (20D)
₹2526

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.